In a recent 8K filing, Zentalis Pharmaceuticals (NASDAQ: ZNTL) announced the immediate resignation of Melissa Epperly from her roles as Chief Financial Officer, Treasurer, principal financial officer, and principal accounting officer, as of April 5, 2024. The company has initiated a search for a new CFO.
Epperly, who has been with Zentalis since February 28, 2023, based on her Amended & Restated Employment Agreement, will receive severance benefits, provided she enters into a release agreement with the company.
Following Epperly's departure, Zentalis' President, Cam Gallagher, has been appointed as the interim CFO, Treasurer, and principal financial officer. Vincent Vultaggio, the Vice President of Finance, will take on the role of interim principal accounting officer. Additionally, Kyle Rasbach, the Chief Business Officer, will temporarily oversee the Investor Relations function.
The Board of Directors made these interim appointments effective on the transition date, which was the same day as Epperly's resignation. The company has not yet announced a permanent replacement for Epperly.
This executive change comes at a time when Zentalis Pharmaceuticals continues to advance in the biopharmaceutical sector. The company, known for its work in cancer treatment development, is now in the process of ensuring a smooth transition in its financial leadership.
Investors and stakeholders are keeping a close watch as Zentalis moves forward with its executive team's restructuring. The information reported is based on the company's statement in a press release.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.